<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04631627</url>
  </required_header>
  <id_info>
    <org_study_id>EPRPLACC</org_study_id>
    <nct_id>NCT04631627</nct_id>
  </id_info>
  <brief_title>Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort</brief_title>
  <official_title>A Prospective Muti-center Study of Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to adopt the method of multi-center prospective randomized controlled&#xD;
      study. The aim of this study is to obtain localized excision values through a preeclampsia&#xD;
      screening model established in early pregnancy, and to evaluate the efficacy of low-dose&#xD;
      aspirin intervention for preeclampsia prevention in pregnant women at high risk of screening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 16, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the rate of preeclampsia</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Hypertensive onset after 20 weeks of gestation is accompanied by proteinuria,or with thrombocytopenia, impaired liver function, renal insufficiency,pulmonary edema,headache without other explanation and so on.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the rate of hypertensive disorder during pregnancy</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>gestational hypertension, preeclampsia, chronic hypertension with preeclampsia, eclampsia, HELLP syndrome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the rate of placenta abruption</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>After 20 weeks of pregnancy, the placenta in its normal position is completely or partially removed from the uterine wall before delivery of the fetus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the rate of fetal growth restriction</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The birth weight of the fetus is below two standard deviations of the average weight for the same gestational age or below the 10th percentile of normal weight for the same age</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the rate of postpartum hemorrhage</measure>
    <time_frame>within 24 hours after the delivery</time_frame>
    <description>Within 24 hours after the delivery of the fetus, the bleeding volume of vaginal delivery ≥500ml, cesarean delivery ≥1000ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the time and type of delivery</measure>
    <time_frame>within 24 hours after the delivery</time_frame>
    <description>gestational week, vaginal delivery and cesarean section</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>birth weight of newborn</measure>
    <time_frame>delivery time</time_frame>
    <description>macrosomia, normal weight, low birth weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar score for newborns</measure>
    <time_frame>delivery time</time_frame>
    <description>≥8；4-7,；≤3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of Neonatal NICU occupancy rate</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>the day of NICU occupancy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>aspirin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aspirin,tablet,100/150mg per day,(BMI&lt;30 100mg/d，BMI≥30 150mg/d)，from pregnancy weeks&lt;16 to 35 weeks or the day of delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>with no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>With the result of risk assessment for high risk and the risk of pregnant women, with each research center stratified random aspirin drug intervention, for each center screening high-risk and accord with the standard drug intervention study phase into eliminate pregnant women by using stochastic indicator 1:1 randomly into low-dose aspirin to prevent group and observation group, for each center in screening for risk and comply with the drug intervention study phase into the exclusion standard 1:1 by random indicator method pregnant women randomly into low-dose aspirin to prevent group and observation group.</description>
    <arm_group_label>aspirin group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1)Pregnant women assessed as at high risk of preeclampsia 2) live pregnancy 3)&#xD;
             gestational weeks &lt; 16 weeks 4) agree to randomized drug intervention studies 5)&#xD;
             follow up regularly and obtain reliable pregnancy outcomes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1)with severe fetal or chromosomal abnormalities 2) induced labor or spontaneous&#xD;
             abortion due to social factors 3) absolute or relative contraindications to aspirin&#xD;
             use (allergy to aspirin or other salicylate, or other ingredients of the drug;Acute&#xD;
             gastrointestinal ulcer;Active bleeding;In patients with severe G6PD deficiency,&#xD;
             acetylsalicylic acid may induce hemolysis or hemolytic anemia.Aspirin asthma)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>gestational women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jinsong Gao, PhD</last_name>
    <phone>18601106857</phone>
    <phone_ext>69155810</phone_ext>
    <email>gaojsong@163.com</email>
  </overall_contact>
  <reference>
    <citation>Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009 Jun;33(3):130-7. doi: 10.1053/j.semperi.2009.02.010. Review.</citation>
    <PMID>19464502</PMID>
  </reference>
  <reference>
    <citation>Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, Gülmezoglu AM, Temmerman M, Alkema L. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014 Jun;2(6):e323-33. doi: 10.1016/S2214-109X(14)70227-X. Epub 2014 May 5. Review.</citation>
    <PMID>25103301</PMID>
  </reference>
  <reference>
    <citation>Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88.</citation>
    <PMID>24150027</PMID>
  </reference>
  <reference>
    <citation>Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33(1):8-15. doi: 10.1159/000341264. Epub 2012 Aug 16. Erratum in: Fetal Diagn Ther. 2013;34(1):43.</citation>
    <PMID>22906914</PMID>
  </reference>
  <reference>
    <citation>Park F, Russo K, Williams P, Pelosi M, Puddephatt R, Walter M, Leung C, Saaid R, Rawashdeh H, Ogle R, Hyett J. Prediction and prevention of early-onset pre-eclampsia: impact of aspirin after first-trimester screening. Ultrasound Obstet Gynecol. 2015 Oct;46(4):419-23. doi: 10.1002/uog.14819. Epub 2015 Aug 31.</citation>
    <PMID>25678383</PMID>
  </reference>
  <reference>
    <citation>Sentilhes L, Azria E, Schmitz T. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017 Dec 14;377(24):2399-400. doi: 10.1056/NEJMc1713798.</citation>
    <PMID>29239588</PMID>
  </reference>
  <reference>
    <citation>FIGO Working Group on Good Clinical Practice in Maternal-Fetal Medicine. Good clinical practice advice: First trimester screening and prevention of pre-eclampsia in singleton pregnancy. Int J Gynaecol Obstet. 2019 Mar;144(3):325-329. doi: 10.1002/ijgo.12741.</citation>
    <PMID>30710362</PMID>
  </reference>
  <reference>
    <citation>Wright D, Nicolaides KH. Aspirin delays the development of preeclampsia. Am J Obstet Gynecol. 2019 Jun;220(6):580.e1-580.e6. doi: 10.1016/j.ajog.2019.02.034. Epub 2019 Feb 21.</citation>
    <PMID>30797761</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 7, 2020</study_first_submitted>
  <study_first_submitted_qc>November 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>November 15, 2020</last_update_submitted>
  <last_update_submitted_qc>November 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>preeclampsia</keyword>
  <keyword>aspirin</keyword>
  <keyword>prediction</keyword>
  <keyword>intervention</keyword>
  <keyword>PAPP-A</keyword>
  <keyword>PIGF</keyword>
  <keyword>sFlt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The aim of this study was to obtain localized excision values through a preeclampsia screening model established in early pregnancy, and to evaluate the efficacy of low-dose aspirin intervention for preeclampsia prevention in pregnant women at high risk of screening.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>31 June, 2022</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

